EA025182B1 - Композиция, включающая афлиберцепт, фолиновую кислоту, 5-фторурацил (5-fu) и ириноцетан (folfiri), для лечения колоректального рака - Google Patents
Композиция, включающая афлиберцепт, фолиновую кислоту, 5-фторурацил (5-fu) и ириноцетан (folfiri), для лечения колоректального рака Download PDFInfo
- Publication number
- EA025182B1 EA025182B1 EA201391577A EA201391577A EA025182B1 EA 025182 B1 EA025182 B1 EA 025182B1 EA 201391577 A EA201391577 A EA 201391577A EA 201391577 A EA201391577 A EA 201391577A EA 025182 B1 EA025182 B1 EA 025182B1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- aflibercept
- patient
- fluorouracil
- dose
- irinocetan
- Prior art date
Links
- 229960002833 aflibercept Drugs 0.000 title claims abstract description 123
- 108010081667 aflibercept Proteins 0.000 title claims abstract description 123
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 title claims abstract description 62
- 229960002949 fluorouracil Drugs 0.000 title claims abstract description 38
- VVIAGPKUTFNRDU-UHFFFAOYSA-N 6S-folinic acid Natural products C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-UHFFFAOYSA-N 0.000 title claims abstract description 35
- 235000008191 folinic acid Nutrition 0.000 title claims abstract description 35
- 239000011672 folinic acid Substances 0.000 title claims abstract description 35
- VVIAGPKUTFNRDU-ABLWVSNPSA-N folinic acid Chemical compound C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-ABLWVSNPSA-N 0.000 title claims abstract description 35
- 229960001691 leucovorin Drugs 0.000 title claims abstract description 35
- MPJKWIXIYCLVCU-UHFFFAOYSA-N Folinic acid Natural products NC1=NC2=C(N(C=O)C(CNc3ccc(cc3)C(=O)NC(CCC(=O)O)CC(=O)O)CN2)C(=O)N1 MPJKWIXIYCLVCU-UHFFFAOYSA-N 0.000 title claims abstract description 31
- 206010009944 Colon cancer Diseases 0.000 title claims abstract description 19
- 208000001333 Colorectal Neoplasms Diseases 0.000 title claims abstract description 19
- 239000000203 mixture Substances 0.000 title description 11
- 238000011282 treatment Methods 0.000 claims abstract description 98
- 238000000034 method Methods 0.000 claims description 46
- 230000004083 survival effect Effects 0.000 claims description 40
- 238000001802 infusion Methods 0.000 claims description 15
- 238000002560 therapeutic procedure Methods 0.000 claims description 15
- 238000002512 chemotherapy Methods 0.000 claims description 13
- 229960000397 bevacizumab Drugs 0.000 claims description 11
- 238000001959 radiotherapy Methods 0.000 claims description 9
- 206010052358 Colorectal cancer metastatic Diseases 0.000 claims description 8
- 229960001756 oxaliplatin Drugs 0.000 claims description 8
- DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 claims description 8
- 238000001356 surgical procedure Methods 0.000 claims description 7
- 208000024891 symptom Diseases 0.000 claims description 5
- 230000001394 metastastic effect Effects 0.000 claims description 3
- 206010061289 metastatic neoplasm Diseases 0.000 claims description 3
- 206010027457 Metastases to liver Diseases 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract description 5
- 229940068196 placebo Drugs 0.000 description 69
- 239000000902 placebo Substances 0.000 description 69
- 238000013517 stratification Methods 0.000 description 23
- 201000003608 Saethre-Chotzen syndrome Diseases 0.000 description 20
- 206010028980 Neoplasm Diseases 0.000 description 14
- 229960004768 irinotecan Drugs 0.000 description 14
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 description 14
- 206010027476 Metastases Diseases 0.000 description 13
- 238000004458 analytical method Methods 0.000 description 11
- 230000034994 death Effects 0.000 description 10
- 231100000517 death Toxicity 0.000 description 10
- 230000000694 effects Effects 0.000 description 9
- 230000002411 adverse Effects 0.000 description 8
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 8
- 238000001990 intravenous administration Methods 0.000 description 8
- 210000004185 liver Anatomy 0.000 description 7
- 230000009401 metastasis Effects 0.000 description 7
- 230000004044 response Effects 0.000 description 7
- 238000011319 anticancer therapy Methods 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- 230000006872 improvement Effects 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 201000011510 cancer Diseases 0.000 description 5
- 210000001072 colon Anatomy 0.000 description 5
- 238000003745 diagnosis Methods 0.000 description 5
- 239000005022 packaging material Substances 0.000 description 5
- 230000009885 systemic effect Effects 0.000 description 5
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 4
- 229940124650 anti-cancer therapies Drugs 0.000 description 4
- 235000019152 folic acid Nutrition 0.000 description 4
- 239000011724 folic acid Substances 0.000 description 4
- 229960000304 folic acid Drugs 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 230000002085 persistent effect Effects 0.000 description 4
- 238000011394 anticancer treatment Methods 0.000 description 3
- 230000000295 complement effect Effects 0.000 description 3
- 230000002028 premature Effects 0.000 description 3
- 210000000664 rectum Anatomy 0.000 description 3
- 230000007480 spreading Effects 0.000 description 3
- 238000011477 surgical intervention Methods 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- 206010012735 Diarrhoea Diseases 0.000 description 2
- 206010061818 Disease progression Diseases 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 2
- 238000011374 additional therapy Methods 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 229960000074 biopharmaceutical Drugs 0.000 description 2
- 230000005750 disease progression Effects 0.000 description 2
- 229960003668 docetaxel Drugs 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 208000010949 lymph node disease Diseases 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 208000003265 stomatitis Diseases 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- WAVYAFBQOXCGSZ-UHFFFAOYSA-N 2-fluoropyrimidine Chemical compound FC1=NC=CC=N1 WAVYAFBQOXCGSZ-UHFFFAOYSA-N 0.000 description 1
- -1 5-RI Chemical compound 0.000 description 1
- 201000004384 Alopecia Diseases 0.000 description 1
- 206010006002 Bone pain Diseases 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 229940123780 DNA topoisomerase I inhibitor Drugs 0.000 description 1
- 206010013886 Dysaesthesia Diseases 0.000 description 1
- 206010013952 Dysphonia Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 206010068790 Ligament pain Diseases 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 108010076504 Protein Sorting Signals Proteins 0.000 description 1
- 101710183280 Topoisomerase Proteins 0.000 description 1
- 239000000365 Topoisomerase I Inhibitor Substances 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 208000009956 adenocarcinoma Diseases 0.000 description 1
- 238000011360 adjunctive therapy Methods 0.000 description 1
- 231100000360 alopecia Toxicity 0.000 description 1
- 125000003275 alpha amino acid group Chemical group 0.000 description 1
- 230000000340 anti-metabolite Effects 0.000 description 1
- 229940100197 antimetabolite Drugs 0.000 description 1
- 239000002256 antimetabolite Substances 0.000 description 1
- 230000002146 bilateral effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004271 bone marrow stromal cell Anatomy 0.000 description 1
- 210000004534 cecum Anatomy 0.000 description 1
- 229960005395 cetuximab Drugs 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 201000010989 colorectal carcinoma Diseases 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 239000002254 cytotoxic agent Substances 0.000 description 1
- 231100000599 cytotoxic agent Toxicity 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 208000001780 epistaxis Diseases 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 208000031066 hyperpigmentation of the skin Diseases 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 229940126601 medicinal product Drugs 0.000 description 1
- 230000003387 muscular Effects 0.000 description 1
- 208000011309 nasal bleeding Diseases 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 208000004235 neutropenia Diseases 0.000 description 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 1
- 210000004789 organ system Anatomy 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 229960001972 panitumumab Drugs 0.000 description 1
- 208000035824 paresthesia Diseases 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 208000037821 progressive disease Diseases 0.000 description 1
- 150000003230 pyrimidines Chemical group 0.000 description 1
- 238000009094 second-line therapy Methods 0.000 description 1
- UQDJGEHQDNVPGU-UHFFFAOYSA-N serine phosphoethanolamine Chemical compound [NH3+]CCOP([O-])(=O)OCC([NH3+])C([O-])=O UQDJGEHQDNVPGU-UHFFFAOYSA-N 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 125000002480 thymidyl group Chemical group 0.000 description 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/178—Lectin superfamily, e.g. selectins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cell Biology (AREA)
- Dermatology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP11305490 | 2011-04-26 | ||
| EP11306154 | 2011-09-15 | ||
| PCT/EP2012/057542 WO2012146610A1 (en) | 2011-04-26 | 2012-04-25 | Composition comprising aflibercept, folinic acid, 5-fluorouracil (5-fu) and irinocetan (folfiri) |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| EA201391577A1 EA201391577A1 (ru) | 2014-03-31 |
| EA025182B1 true EA025182B1 (ru) | 2016-11-30 |
Family
ID=46001286
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA201391577A EA025182B1 (ru) | 2011-04-26 | 2012-04-25 | Композиция, включающая афлиберцепт, фолиновую кислоту, 5-фторурацил (5-fu) и ириноцетан (folfiri), для лечения колоректального рака |
Country Status (39)
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JO3283B1 (ar) | 2011-04-26 | 2018-09-16 | Sanofi Sa | تركيب يتضمن أفليبيرسيبت, حمض فولينيك, 5- فلورويوراسيل (5- Fu) وإرينوسيتان (FOLFIRI) |
| US9717724B2 (en) | 2012-06-13 | 2017-08-01 | Ipsen Biopharm Ltd. | Methods for treating pancreatic cancer using combination therapies |
| AU2013202947B2 (en) * | 2012-06-13 | 2016-06-02 | Ipsen Biopharm Ltd. | Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan |
| JP2015526430A (ja) * | 2012-08-02 | 2015-09-10 | サノフイ | アフリベルセプトまたはｚｉｖ−アフリベルセプトを含む製造物品 |
| US9840553B2 (en) | 2014-06-28 | 2017-12-12 | Kodiak Sciences Inc. | Dual PDGF/VEGF antagonists |
| MA40354A (fr) * | 2014-07-18 | 2017-05-24 | Sanofi Sa | Procédé permettant de prédire le résultat d'un traitement avec de l'aflibercept d'un patient suspecté de souffrir d'un cancer |
| CN107076749B (zh) | 2014-09-16 | 2020-12-29 | 瑞泽恩制药公司 | 转移性结直肠癌抗血管发生治疗相关预测和预后生物标志 |
| US11318131B2 (en) | 2015-05-18 | 2022-05-03 | Ipsen Biopharm Ltd. | Nanoliposomal irinotecan for use in treating small cell lung cancer |
| PL3337467T3 (pl) | 2015-08-20 | 2021-06-14 | Ipsen Biopharm Ltd. | Terapia skojarzona z zastosowaniem liposomalnego irynotekanu i inhibitora parp do leczenia nowotworu |
| IL257149B2 (en) | 2015-08-21 | 2024-11-01 | Ipsen Biopharm Ltd | Methods for treating metastatic pancreatic cancer using combination therapies comprising liposomal irinotecan and oxaliplatin |
| KR101936049B1 (ko) * | 2015-10-15 | 2019-01-08 | (주)알테오젠 | IgG Fc 도메인을 가지는 융합 단백질의 생산방법 |
| BR112018013407A2 (en) | 2015-12-30 | 2018-12-18 | Kodiak Sciences Inc. | antibodies and conjugates thereof |
| ES2908848T3 (es) * | 2016-01-25 | 2022-05-04 | Sanofi Sa | Método de predicción del resultado de un tratamiento con aflibercept de un paciente que se sospecha que padece un cáncer midiendo el nivel de un biomarcador de plasma |
| EP3535026A1 (en) | 2016-11-02 | 2019-09-11 | Ipsen Biopharm Limited | Treating gastric cancer using combination therapies comprising liposomal irinotecan, oxaliplatin, 5-fluoruracil (and leucovorin) |
| SG11202008242XA (en) | 2018-03-02 | 2020-09-29 | Kodiak Sciences Inc | Il-6 antibodies and fusion constructs and conjugates thereof |
| SG11202010684YA (en) | 2018-05-10 | 2020-11-27 | Regeneron Pharma | High concentration vegf receptor fusion protein containing formulations |
| CA3101694A1 (en) * | 2018-05-30 | 2019-12-05 | David MACHOVER | Methods and pharmaceutical compositions for treating cancer |
| WO2021050094A1 (en) * | 2019-09-11 | 2021-03-18 | Adverum Biotechnologies, Inc. | Methods of treating ocular neovascular diseases using aav2 variants encoding aflibercept |
| US11912784B2 (en) | 2019-10-10 | 2024-02-27 | Kodiak Sciences Inc. | Methods of treating an eye disorder |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006059012A1 (fr) * | 2004-12-03 | 2006-06-08 | Aventis Pharma S.A. | Combinaisons antitumorales contenant un agent inhibiteur de vegf et du 5fu ou un de ses derives |
| WO2009024667A2 (fr) * | 2007-07-05 | 2009-02-26 | Aventis Pharma S.A. | Combinaisons antitumorales contenant un agent inhibiteur de vegf et de l'irinotecan |
Family Cites Families (95)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS6019790B2 (ja) | 1977-11-18 | 1985-05-17 | 株式会社日立製作所 | 光硬化型接着性組成物とそれを用いて被着体を接着する方法 |
| US4353887A (en) | 1979-08-16 | 1982-10-12 | Ciba-Geigy Corporation | Divisible tablet having controlled and delayed release of the active substance |
| JPS6019790A (ja) | 1983-07-14 | 1985-01-31 | Yakult Honsha Co Ltd | 新規なカンプトテシン誘導体 |
| WO1993000807A1 (en) | 1991-07-03 | 1993-01-21 | Cryolife, Inc. | Method for stabilization of biomaterials |
| US5474796A (en) | 1991-09-04 | 1995-12-12 | Protogene Laboratories, Inc. | Method and apparatus for conducting an array of chemical reactions on a support surface |
| US6749853B1 (en) | 1992-03-05 | 2004-06-15 | Board Of Regents, The University Of Texas System | Combined methods and compositions for coagulation and tumor treatment |
| DE69333928T2 (de) | 1992-04-30 | 2006-08-17 | Probitas Pharma Inc., Los Angeles | Verbesserte solubilisierung und stabilisierung des faktor viii-komplexes |
| US6177401B1 (en) | 1992-11-13 | 2001-01-23 | Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften | Use of organic compounds for the inhibition of Flk-1 mediated vasculogenesis and angiogenesis |
| ATE281469T1 (de) | 1993-03-25 | 2004-11-15 | Merck & Co Inc | Inhibitor des wachstumsfaktors für gefäss- endothelzellen |
| US6811779B2 (en) | 1994-02-10 | 2004-11-02 | Imclone Systems Incorporated | Methods for reducing tumor growth with VEGF receptor antibody combined with radiation and chemotherapy |
| US6040157A (en) | 1994-03-08 | 2000-03-21 | Human Genome Sciences, Inc. | Vascular endothelial growth factor 2 |
| GB9410533D0 (en) | 1994-05-26 | 1994-07-13 | Lynxvale Ltd | In situ hybridisation and immuno-Chemical localisation of a growth factor |
| GB9410534D0 (en) | 1994-05-26 | 1994-07-13 | Lynxvale Ltd | Improvements in or relating to growth factor inhibitors |
| TW438775B (en) | 1995-04-07 | 2001-06-07 | Pharmacia & Upjohn Co Llc | Novel intermediates and process for the manufacture of camptothecin derivatives (CPT-11) and related compounds |
| US6685940B2 (en) | 1995-07-27 | 2004-02-03 | Genentech, Inc. | Protein formulation |
| US6267958B1 (en) | 1995-07-27 | 2001-07-31 | Genentech, Inc. | Protein formulation |
| JPH09154588A (ja) | 1995-10-07 | 1997-06-17 | Toagosei Co Ltd | Ｖｅｇｆ結合性ポリペプチド |
| US6100071A (en) | 1996-05-07 | 2000-08-08 | Genentech, Inc. | Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production |
| US5763401A (en) | 1996-07-12 | 1998-06-09 | Bayer Corporation | Stabilized albumin-free recombinant factor VIII preparation having a low sugar content |
| AU738806B2 (en) | 1996-09-24 | 2001-09-27 | Merck & Co., Inc. | Gene therapy for inhibition of angiogenesis |
| US7312196B2 (en) | 1997-01-08 | 2007-12-25 | Amylin Pharmaceuticals, Inc. | Formulations for amylin agonist peptides |
| DE19724793A1 (de) | 1997-06-06 | 1998-12-10 | Schering Ag | D-mutierte Peptide mit VEGF-Rezeptor blockierenden Eigenschaften |
| US6075007A (en) | 1997-07-17 | 2000-06-13 | Regeneron Pharmaceuticals, Inc. | Modified noggin polypeptide and compositions |
| JPH1180024A (ja) | 1997-09-12 | 1999-03-23 | Toagosei Co Ltd | 角膜血管新生阻害剤 |
| US6436897B2 (en) | 1998-06-01 | 2002-08-20 | Celtrix Pharmaceuticals, Inc. | Pharmaceutical formulations for IGF/IGFBP |
| DE19841985A1 (de) | 1998-09-03 | 2000-03-09 | Schering Ag | Dialkylsulfonsäure- und Dialkylcarbonsäure-Derivate |
| US6472179B2 (en) | 1998-09-25 | 2002-10-29 | Regeneron Pharmaceuticals, Inc. | Receptor based antagonists and methods of making and using |
| WO2000034337A1 (en) | 1998-12-10 | 2000-06-15 | Tsukuba Research Laboratory, Toagosei Co., Ltd. | Humanized monoclonal antibodies against vascular endothelial cell growth factor |
| AP1243A (en) | 1999-02-01 | 2004-02-02 | Servier Lab | Core tablet for controlled release of gliclazide after oral administration. |
| ES2223705T3 (es) | 1999-04-28 | 2005-03-01 | Board Of Regents, The University Of Texas System | Composiciones y metodos para el tratamiento de cancer mediante inhibi cion selectiva del vegf. |
| AU4564200A (en) | 1999-04-29 | 2000-11-17 | Aventis Pharma S.A. | Method for treating cancer using camptothecin derivatives and 5-fluorouracil |
| US6833349B2 (en) | 1999-06-08 | 2004-12-21 | Regeneron Pharmaceuticals, Inc. | Methods of treating inflammatory skin diseases |
| US7087411B2 (en) | 1999-06-08 | 2006-08-08 | Regeneron Pharmaceuticals, Inc. | Fusion protein capable of binding VEGF |
| US7396664B2 (en) | 1999-06-08 | 2008-07-08 | Regeneron Pharmaceuticals, Inc. | VEGF-binding fusion proteins and nucleic acids encoding the same |
| US7303746B2 (en) | 1999-06-08 | 2007-12-04 | Regeneron Pharmaceuticals, Inc. | Methods of treating eye disorders with modified chimeric polypeptides |
| US7306799B2 (en) | 1999-06-08 | 2007-12-11 | Regeneron Pharmaceuticals, Inc. | Use of VEGF inhibitors for treatment of eye disorders |
| US7070959B1 (en) | 1999-06-08 | 2006-07-04 | Regeneron Pharmaceuticals, Inc. | Modified chimeric polypeptides with improved pharmacokinetic properties |
| RS50073B (sr) | 1999-06-08 | 2009-01-22 | Regeneron Pharmaceuticals I.N.C., | Modifikovani himerni polipeptidi sa poboljšanim farmakokinetičkim osobinama |
| US7001892B1 (en) | 1999-06-11 | 2006-02-21 | Purdue Research Foundation | Pharmaceutical materials and methods for their preparation and use |
| DE19938724A1 (de) | 1999-08-16 | 2001-02-22 | Tetra Laval Holdings & Finance | Vorrichtung zur Herstellung von Kunststoffbehältern mittels Streckblasformen |
| GB0008269D0 (en) | 2000-04-05 | 2000-05-24 | Astrazeneca Ab | Combination chemotherapy |
| US6500633B1 (en) | 2000-04-26 | 2002-12-31 | Atairgin Technologies, Inc. | Method of detecting carcinomas |
| GT200100079A (es) | 2000-05-10 | 2001-12-31 | Metodo para regular la angiogenesis utilizando proteina ryk | |
| PT1324776E (pt) | 2000-10-12 | 2009-12-23 | Genentech Inc | Formulações de proteína concentradas de viscosidade reduzida |
| US20030092019A1 (en) | 2001-01-09 | 2003-05-15 | Millennium Pharmaceuticals, Inc. | Methods and compositions for diagnosing and treating neuropsychiatric disorders such as schizophrenia |
| US20040023864A1 (en) | 2001-05-09 | 2004-02-05 | Steve Roczniak | Method of regulating angiogenesis using ryk protein |
| WO2003009817A2 (en) | 2001-07-25 | 2003-02-06 | Protein Design Labs, Inc. | Stable lyophilized pharmaceutical formulation of igg antibodies |
| ES2287495T3 (es) | 2002-03-01 | 2007-12-16 | Pfizer Italia S.R.L. | Forma polimorfa cristalina de clorhidrato de irinotecan. |
| JP2004006671A (ja) | 2002-03-22 | 2004-01-08 | Sanyo Electric Co Ltd | 電荷結合素子およびその製造方法 |
| PT1608685E (pt) | 2003-03-28 | 2007-05-31 | Regeneron Pharma | Anatagonistas de vegf para o tratamento de diabetes. |
| HRP20050934B1 (hr) | 2003-04-04 | 2014-09-26 | Genentech, Inc. | Formulacije s visokom koncentracijom antitijela i proteina |
| US7300654B2 (en) | 2003-05-28 | 2007-11-27 | Regeneron Pharmaceuticals, Inc. | Method of treating corneal transplant rejection in high risk keratoplasty patients |
| CA2519835A1 (en) | 2003-05-28 | 2004-12-09 | Regeneron Pharmaceuticals, Inc. | Method of treating corneal transplant rejection |
| US7186699B2 (en) | 2003-06-03 | 2007-03-06 | Cell Genesys, Inc. | Method for treating cancer by vector-mediated delivery of one or more anti-angiogenic or pro-apoptotic genes |
| CA2519875C (en) | 2003-06-06 | 2014-01-14 | Regeneron Pharmaceuticals, Inc. | Method of tumor regression with vegf inhibitors |
| US7399612B2 (en) | 2003-06-30 | 2008-07-15 | Regeneron Pharmaceuticals, Inc. | VEGF-binding fusion proteins and nucleic acids encoding the same |
| AR046510A1 (es) | 2003-07-25 | 2005-12-14 | Regeneron Pharma | Composicion de un antagonista de vegf y un agente anti-proliferativo |
| US20050196340A1 (en) | 2003-08-06 | 2005-09-08 | Jocelyn Holash | Use of a VEGF antagonist in combination with radiation therapy |
| US20050112061A1 (en) | 2003-08-06 | 2005-05-26 | Jocelyn Holash | Use of a VEGF antagonist in combination with radiation therapy |
| CN1802627B (zh) | 2003-08-14 | 2010-04-28 | 富士通株式会社 | 计算机装置和集群服务器装置 |
| AU2004268614C1 (en) | 2003-08-27 | 2010-10-28 | Ophthotech Corporation | Combination therapy for the treatment of ocular neovascular disorders |
| DE60326353D1 (de) | 2003-11-06 | 2009-04-09 | Nestle Waters Man & Technology | Herstellungsverfahren von Behältern aus Polyesterharz |
| WO2005046602A2 (en) | 2003-11-10 | 2005-05-26 | Greenville Hospital System | Vegf receptor antagonists |
| WO2005072772A1 (en) | 2004-01-30 | 2005-08-11 | Suomen Punainen Risti Veripalvelu | Pharmaceutical compositions |
| JP2008502738A (ja) | 2004-06-10 | 2008-01-31 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | ヒトの癌を処置するための、ｖｅｇｆインヒビターの使用 |
| MXPA06014689A (es) | 2004-06-18 | 2008-03-11 | Regeneron Pharma | Inhibidores del vegf para el tratamiento de efusion pleural maligna. |
| MX2007001241A (es) | 2004-07-30 | 2007-07-11 | Regeneron Pharma | Metodos para tratar diabetes tipo i mediante el bloqueo de la actividad mediada de vegf. |
| RS52539B (sr) | 2004-10-21 | 2013-04-30 | Genentech Inc. | Metod za tretiranje intraokularnih neovaskularnih bolesti |
| EP1877438A2 (en) | 2005-02-02 | 2008-01-16 | Regeneron Pharmaceuticals, Inc. | Method of treating eye injury with local administration of a vegf inhibitor |
| EP1853298A2 (en) | 2005-02-11 | 2007-11-14 | Regeneron Pharmaceuticals, Inc. | Therapeutic combination of a vegf antagonist (vegf trap) and an anti-hypertensive agent |
| CA2598452A1 (en) | 2005-03-11 | 2006-09-21 | Regeneron Pharmaceuticals, Inc. | Treating anemia by inhibition of vegf |
| EP2586459B1 (en) | 2005-03-25 | 2017-05-24 | Regeneron Pharmaceuticals, Inc. | Vegf antagonist formulations |
| CN101237880B (zh) | 2005-08-12 | 2011-09-21 | 瑞泽恩制药公司 | 通过vegf拮抗剂的皮下给药治疗疾病 |
| US7354582B2 (en) | 2006-03-10 | 2008-04-08 | Regeneron Pharmaceuticals, Inc. | Use of VEGF antagonists for the treatment of malignant gliomas |
| EP3753548A1 (en) | 2006-06-16 | 2020-12-23 | Regeneron Pharmaceuticals, Inc. | Vegf antagonist formulations suitable for intravitreal administration |
| NO347649B1 (no) | 2006-12-14 | 2024-02-12 | Regeneron Pharma | Humant antistoff eller antistoff fragment som spesifikt binder human deltaliknende ligand 4 (hDII4), nukleinsyremolekyl som koder for slike og vektor og vert-vektorsystemer, samt fremgangsmåte for fremstilling, sammensetning og anvendelse. |
| EP2136630A4 (en) | 2007-03-23 | 2010-06-02 | Precision Therapeutics Inc | METHOD FOR EVALUATING THE ANGIOGENIC POTENTIAL IN CULTURE |
| CN100546578C (zh) * | 2007-08-10 | 2009-10-07 | 河北医科大学 | 一种抗癌药物组合物及其在制备抗癌药物中的应用 |
| JP5734656B2 (ja) | 2007-10-04 | 2015-06-17 | オニキス セラピューティクス， インク．Ｏｎｙｘ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． | ペプチドエポキシケトンプロテアーゼ阻害剤結晶及びアミノ酸ケトエポキシドの調製 |
| AU2008334070B2 (en) | 2007-11-30 | 2015-04-16 | Genentech, Inc. | VEGF polymorphisms and anti-angiogenesis therapy |
| EP2143542A1 (fr) | 2008-07-07 | 2010-01-13 | Nestec S.A. | Procédé et dispositif de conditionnement d'un liquide alimentaire |
| FR2933702A1 (fr) | 2008-07-08 | 2010-01-15 | Sanofi Aventis | Antagonistes specifiques du recepteur fgf-r4 |
| WO2010022201A2 (en) | 2008-08-22 | 2010-02-25 | Osteogenex Inc. | Folinic acid derivatives for promoting bone growth |
| US20100093552A1 (en) | 2008-10-09 | 2010-04-15 | Asit Panja | Use and identification of biomarkers for gastrointestinal diseases |
| EP2356250A2 (en) | 2008-11-05 | 2011-08-17 | Genentech, Inc. | Genetic polymorphisms in age-related macular degeneration |
| CA2754646A1 (en) | 2009-03-31 | 2010-10-07 | Roche Glycart Ag | Treatment of cancer with a humanized anti-egfr igg1 antibody and irinotecan |
| WO2010124264A2 (en) | 2009-04-24 | 2010-10-28 | University Of Southern California | Genetic variants in angiogenesis pathway associated with clinical outcome |
| WO2011014759A2 (en) | 2009-07-31 | 2011-02-03 | Amcor Limited | Hot-fill container |
| US8221753B2 (en) * | 2009-09-30 | 2012-07-17 | Tracon Pharmaceuticals, Inc. | Endoglin antibodies |
| WO2012123227A1 (en) | 2011-02-23 | 2012-09-20 | Sanofi | Single nucleotide polymorphisms in the promoter of vegfa gene and their use as predictive markers for anti-vegf treatments |
| JO3283B1 (ar) | 2011-04-26 | 2018-09-16 | Sanofi Sa | تركيب يتضمن أفليبيرسيبت, حمض فولينيك, 5- فلورويوراسيل (5- Fu) وإرينوسيتان (FOLFIRI) |
| JP6019790B2 (ja) | 2012-06-19 | 2016-11-02 | 富士電機株式会社 | 接合方法及び接合部材 |
| JP2015526430A (ja) | 2012-08-02 | 2015-09-10 | サノフイ | アフリベルセプトまたはｚｉｖ−アフリベルセプトを含む製造物品 |
| MA40354A (fr) | 2014-07-18 | 2017-05-24 | Sanofi Sa | Procédé permettant de prédire le résultat d'un traitement avec de l'aflibercept d'un patient suspecté de souffrir d'un cancer |
| ES2908848T3 (es) | 2016-01-25 | 2022-05-04 | Sanofi Sa | Método de predicción del resultado de un tratamiento con aflibercept de un paciente que se sospecha que padece un cáncer midiendo el nivel de un biomarcador de plasma |
-
2012
- 2012-04-24 JO JOP/2012/0097A patent/JO3283B1/ar active
- 2012-04-25 LT LTEP12717129.6T patent/LT2701724T/lt unknown
- 2012-04-25 EP EP17157891.7A patent/EP3210617A1/en not_active Withdrawn
- 2012-04-25 WO PCT/EP2012/057542 patent/WO2012146610A1/en not_active Ceased
- 2012-04-25 CA CA2833592A patent/CA2833592A1/en active Pending
- 2012-04-25 AR ARP120101420A patent/AR086051A1/es unknown
- 2012-04-25 SG SG2013079058A patent/SG194613A1/en unknown
- 2012-04-25 KR KR1020197020546A patent/KR20190088568A/ko not_active Ceased
- 2012-04-25 UA UAA201313713A patent/UA114708C2/uk unknown
- 2012-04-25 MX MX2013012387A patent/MX341348B/es active IP Right Grant
- 2012-04-25 KR KR1020137030891A patent/KR102002653B1/ko active Active
- 2012-04-25 DK DK12717129.6T patent/DK2701724T3/en active
- 2012-04-25 ES ES12717129.6T patent/ES2637074T3/es active Active
- 2012-04-25 RS RS20170801A patent/RS56177B1/sr unknown
- 2012-04-25 BR BR112013027356A patent/BR112013027356A2/pt not_active Application Discontinuation
- 2012-04-25 SI SI201231040T patent/SI2701724T1/sl unknown
- 2012-04-25 EP EP12717129.6A patent/EP2701724B1/en active Active
- 2012-04-25 PL PL12717129T patent/PL2701724T3/pl unknown
- 2012-04-25 PE PE2017001505A patent/PE20171516A1/es unknown
- 2012-04-25 HR HRP20171216TT patent/HRP20171216T1/hr unknown
- 2012-04-25 SG SG10201610829UA patent/SG10201610829UA/en unknown
- 2012-04-25 AU AU2012247530A patent/AU2012247530B2/en active Active
- 2012-04-25 PE PE2013002411A patent/PE20140616A1/es not_active Application Discontinuation
- 2012-04-25 PH PH1/2013/502195A patent/PH12013502195A1/en unknown
- 2012-04-25 CN CN201280031198.9A patent/CN103608029A/zh active Pending
- 2012-04-25 PT PT127171296T patent/PT2701724T/pt unknown
- 2012-04-25 JP JP2014506843A patent/JP6114257B2/ja active Active
- 2012-04-25 HU HUE12717129A patent/HUE034288T2/en unknown
- 2012-04-25 US US14/113,757 patent/US11033606B2/en active Active
- 2012-04-25 EA EA201391577A patent/EA025182B1/ru not_active IP Right Cessation
- 2012-04-26 TW TW101115009A patent/TWI599369B/zh active
- 2012-04-26 UY UY0001034036A patent/UY34036A/es not_active Application Discontinuation
-
2013
- 2013-10-17 IL IL228947A patent/IL228947B/en active IP Right Grant
- 2013-10-18 NI NI201300112A patent/NI201300112A/es unknown
- 2013-10-22 DO DO2013000248A patent/DOP2013000248A/es unknown
- 2013-10-23 GT GT201300260A patent/GT201300260A/es unknown
- 2013-10-24 CR CR20130547A patent/CR20130547A/es unknown
- 2013-10-24 CL CL2013003082A patent/CL2013003082A1/es unknown
- 2013-11-20 MA MA36457A patent/MA35130B1/fr unknown
- 2013-11-22 ZA ZA2013/08821A patent/ZA201308821B/en unknown
- 2013-11-25 EC ECSP13013044 patent/ECSP13013044A/es unknown
- 2013-11-26 CO CO13277422A patent/CO6811861A2/es unknown
-
2017
- 2017-08-22 CY CY20171100890T patent/CY1120382T1/el unknown
-
2018
- 2018-01-28 IL IL257179A patent/IL257179A/en unknown
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006059012A1 (fr) * | 2004-12-03 | 2006-06-08 | Aventis Pharma S.A. | Combinaisons antitumorales contenant un agent inhibiteur de vegf et du 5fu ou un de ses derives |
| WO2009024667A2 (fr) * | 2007-07-05 | 2009-02-26 | Aventis Pharma S.A. | Combinaisons antitumorales contenant un agent inhibiteur de vegf et de l'irinotecan |
Non-Patent Citations (2)
| Title |
|---|
| HURWITZ H, ET AL.: "BAVACIZUMAB PLUS IRINOTECAN, FLUOROURACIL, AND LEUCOVORIN FOR METASTATIC COLORECTAL CANCER", NEW ENGLAND JOURNAL OF MEDICINE, THE - NEJM, MASSACHUSETTS MEDICAL SOCIETY, US, vol. 350, no. 23, 3 June 2004 (2004-06-03), US, pages 2335 - 2342, XP009038752, ISSN: 1533-4406, DOI: 10.1056/NEJMoa032691 * |
| SANOFI-REGENERON: "Aflibercept Versus Placebo in Combination With Irinotecan and 5-FU in theTreatment of Patients With Metastatic Colorectal Cancer After Failure of an Oxaliplatin Based Regimen", 17 February 2011 (2011-02-17), pages 1 - 3, XP002677282, Retrieved from the Internet <URL:http://clinicaltrials.gov/archive/NCT00561470/2011_02_17>> [retrieved on 20120605] * |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA025182B1 (ru) | Композиция, включающая афлиберцепт, фолиновую кислоту, 5-фторурацил (5-fu) и ириноцетан (folfiri), для лечения колоректального рака | |
| JP7482180B2 (ja) | 癌のための併用療法 | |
| KR20250134209A (ko) | 키메라 항원 수용체에 관한 방법 및 조성물 | |
| RS57520B1 (sr) | Postupci za lečenje atopijskog dermatitisa primenom antagonista il-4r | |
| JP2018525438A (ja) | がんの処置における免疫調節剤とｐｄ−１またはｐｄ−ｌ１チェックポイント阻害剤との組合せ | |
| US20140017264A1 (en) | Dosage and administration of bispecific scfv conjugates | |
| NL2024544B1 (en) | Compositions And Methods For Cancer Therapy | |
| EP3819312A1 (en) | Dosing regimen for anti-dll3 agents | |
| JP2019517508A5 (enExample) | ||
| EP3976193A1 (en) | Dosing of bispecific t cell engager | |
| JP2011506436A (ja) | 細胞傷害性ｔリンパ球抗原４（ｃｔｌａ４）に対する抗体と組み合わせられたアルファチモシンペプチドによる黒色腫の処置の方法 | |
| EP4021940A1 (en) | Methods and combinations for the treatment of cancer using immune checkpoint inhibitor antibodies | |
| US20210196744A1 (en) | Compositions for cancer therapy and methods | |
| WO2018187259A1 (en) | Methods and compositions for stimulating the immune system | |
| ES2880950T3 (es) | Terapia de anticuerpos contra el VIH como sustituto del tratamiento | |
| WO2017176565A1 (en) | Combinations of an anti-b7-h1 antibody and a cxcr4 peptide antagonist for treating a solid tumor | |
| KR102624844B1 (ko) | 암의 향상된 치료 | |
| US20200093789A1 (en) | Cancer Treatment with a CXCL12 Signaling Inhibitor and an Immune Checkpoint Inhibitor | |
| JP7504106B2 (ja) | がんの処置のための組合せ物 | |
| EP4493185A1 (en) | Treatment of breast cancer with amcenestrant | |
| TW202304512A (zh) | 雙特異性t細胞銜接體之給藥 | |
| Trédaniel et al. | Final results of the IFCT-0803 study, a phase II study of cetuximab, pemetrexed, cisplatin, and concurrent radiotherapy in patients with locally advanced, unresectable, stage III, non-squamous, non-small-cell lung cancer | |
| US20250019441A1 (en) | Treatment of cancer with anti-ilt2 antibodies | |
| Frasci et al. | Gemcitabine/cyclophosphamide/5-fluorouracil/folinic acid triplet combination in anthracycline-and taxane-refractory breast cancer patients: a Southern Italy Cooperative Oncology Group phase I/II study | |
| WO2018060418A1 (en) | Substance selected among irinotecan, an irinotecan active metabolite, 5-fluoro-uracile, a pharmaceutical salt thereof and a mixture thereof, for use in the treatment of fibrosis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM4A | Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s) |
Designated state(s): AM AZ BY KG MD TJ TM |
|
| MM4A | Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s) |
Designated state(s): KZ |